TY - JOUR
T1 - Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of pcv10 and pcv13
T2 - Findings from the pserenade project
AU - PSERENADE Team
AU - Bennett, Julia C.
AU - Hetrich, Marissa K.
AU - Quesada, Maria Garcia
AU - Sinkevitch, Jenna N.
AU - Knoll, Maria Deloria
AU - Feikin, Daniel R.
AU - Zeger, Scott L.
AU - Kagucia, Eunice W.
AU - Cohen, Adam L.
AU - Ampofo, Krow
AU - Brandileone, Maria Cristina C.
AU - Bruden, Dana
AU - Camilli, Romina
AU - Castilla, Jesús
AU - Chan, Guanhao
AU - Cook, Heather
AU - Cornick, Jennifer E.
AU - Dagan, Ron
AU - Dalby, Tine
AU - Danis, Kostas
AU - de Miguel, Sara
AU - De Wals, Philippe
AU - Desmet, Stefanie
AU - Georgakopoulou, Theano
AU - Gilkison, Charlotte
AU - Grgic‐vitek, Marta
AU - Hammitt, Laura L.
AU - Hilty, Markus
AU - Ho, Pak Leung
AU - Jayasinghe, Sanjay
AU - Kellner, James D.
AU - Kleynhans, Jackie
AU - Knol, Mirjam J.
AU - Kozakova, Jana
AU - Kristinsson, Karl G.
AU - Ladhani, Shamez N.
AU - Macdonald, Laura
AU - Mackenzie, Grant A.
AU - Mad’arová, Lucia
AU - McGeer, Allison
AU - Mereckiene, Jolita
AU - Morfeldt, Eva
AU - Mungun, Tuya
AU - Muñoz‐almagro, Carmen
AU - Nuorti, J. Pekka
AU - Paragi, Metka
AU - Pilishvili, Tamara
AU - Puentes, Rodrigo
AU - Saha, Samir K.
AU - Hayford, Kyla
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/4
Y1 - 2021/4
N2 - Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococ-cal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) con-taining ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERE‐ NADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) compar-ing the pre‐PCV10/13 period to each post‐PCV10/13 year by site using a Bayesian multi‐level, mixed-effects Poisson regression and all‐site IRRs using a linear mixed‐effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all‐site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.
AB - Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococ-cal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) con-taining ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERE‐ NADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) compar-ing the pre‐PCV10/13 period to each post‐PCV10/13 year by site using a Bayesian multi‐level, mixed-effects Poisson regression and all‐site IRRs using a linear mixed‐effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all‐site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.
KW - Invasive pneumococcal disease
KW - Pneumococcal conjugate vaccines
KW - Serotypes
KW - Vaccine impact
UR - http://www.scopus.com/inward/record.url?scp=85103077847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103077847&partnerID=8YFLogxK
U2 - 10.3390/microorganisms9040696
DO - 10.3390/microorganisms9040696
M3 - Article
C2 - 33801760
AN - SCOPUS:85103077847
SN - 2076-2607
VL - 9
JO - Microorganisms
JF - Microorganisms
IS - 4
M1 - 696
ER -